Evidence map›Paper›PMID 37660314›Full record

ArticleArchives of virology2023

Genome characterization of the novel lytic phage vB_AbaAut_ChT04 and the antimicrobial activity of its lysin peptide against Acinetobacter baumannii isolates from different time periods.

Udomluk Leungtongkam, Thawatchai Kitti, Supat Khongfak, Rapee Thummeepak, Kannipa Tasanapak, Jintana Wongwigkarn, Sophit Khanthawong, Aouatif Belkhiri, Henrique G Ribeiro, John S Turner and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Phage Therapy forAntibiotics (Basel, Switzerland) · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Udomluk LeungtongkamDepartment of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.
Thawatchai KittiDepartment of Oriental Medicine, Chiang Rai College, Chiangrai, Thailand.
Supat KhongfakDepartment of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.
Rapee ThummeepakDepartment of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.
Kannipa TasanapakDepartment of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.
Jintana WongwigkarnDepartment of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.
Sophit KhanthawongDepartment of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.
Aouatif BelkhiriChemical Engineering Department, Loughborough University, Loughborough, UK.
Henrique G RibeiroChemical Engineering Department, Loughborough University, Loughborough, UK.
John S TurnerChemical Engineering Department, Loughborough University, Loughborough, UK.
Danish J MalikChemical Engineering Department, Loughborough University, Loughborough, UK.
Sutthirat SitthisakDepartment of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand. sutthirats@nu.ac.th.ORCID http://orcid.org/0000-0003-4992-7635

Funding

Royal Golden Jubilee (RGJ) Ph.D. Programme PHD/0227/2560Thailand Research Fund and Naresuan University under the Mid-career Researcher grant RSA6180042
6 · The paper itself

Abstract

Acinetobacter baumannii is an important opportunistic pathogen, usually associated with immunocompromised individuals with a prolonged period of stay in a hospital. Currently, the incidence of multi-drug resistant A. baumannii (MDR-AB) and extensively drug-resistant A. baumannii (XDR-AB) is increasing rapidly in Thailand, mirroring the trend worldwide. Novel therapeutic approaches for the treatment of A. baumannii infection using bacteriophages are being evaluated, and the use of phage-derived peptides is being tested as alternative approach to fighting infection. In this study, we isolated and determined the biological features of a lytic A. baumannii phage called vB_AbaAut_ChT04 (vChT04). The vChT04 phage was classified as a member of the family Autographiviridae of the class Caudoviricetes. It showed a short latent period (10 min) and a large burst size (280 PFU cell

Indexed as

Acinetobacter baumanniiAnti-Infective AgentsBacteriophagesCaudoviralesHumansPeptidesAnti-Infective AgentsPeptides

Identifiers

PMID37660314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.